SCHEMBL2628599

SCHEMBL2628599

CC(=O)c1cc(N)cc(N)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA5A P35218 1/20 0.52
MAPT P10636 3/20 0.45
RAB9A P51151 3/20 0.45
NPC1 O15118 2/20 0.45
LMNA P02545 3/20 0.43
CREBBP Q92793 1/20 0.42
PRKCI P41743 1/20 0.42
FURIN P09958 1/20 0.41
KDM4E B2RXH2 3/20 0.40
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
NOS3 P29474 2/20 0.38
NOS1 P29475 2/20 0.38
ALDH1A1 P00352 1/20 0.38
DDO Q99489 1/20 0.38
CA2 P00918 1/20 0.38
HPGD P15428 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
PBRM1 Q86U86 1/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1976289 0.94 CA5A (0.52) CA5AMAPTRAB9ANPC1LMNA
SCHEMBL10066340 0.85 TSHR (0.55) CA5AMAPTRAB9ANPC1LMNA
SCHEMBL4730653 0.85 FURIN (0.45) CA5AMAPTRAB9ANPC1LMNA
SCHEMBL12666031 0.85 TPMT (0.50) CA5AMAPTRAB9ANPC1LMNA
SCHEMBL17635528 0.84 CA5A (0.43) CA5AMAPTRAB9ANPC1LMNA
SCHEMBL15338597 0.84 CA5A (0.43) CA5AMAPTRAB9ANPC1LMNA
SCHEMBL13307461 0.80 CA5A (0.40) CA5AMAPTRAB9ANPC1LMNA
SCHEMBL14192216 0.80 CA5A (0.40) CA5AMAPTRAB9ANPC1LMNA
SCHEMBL4731090 0.80 CA12 (0.50) MAPTLMNACREBBPKDM4EALDH1A1
SCHEMBL12187779 0.80 CA5A (0.40) CA5AMAPTRAB9ANPC1CREBBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120136703-A Compound, polymer, composition for film formation, pattern formation method, method for forming insulating film, and method for producing compound 三菱瓦斯化学株式会社 2025-06-13 CN disclosed
CN-120136704-A Compound, polymer, composition for film formation, pattern formation method, method for forming insulating film, and method for producing compound 三菱瓦斯化学株式会社 2025-06-13 CN disclosed
US-20220348698-A1 COMPOUND, POLYMER, COMPOSITION, COMPOSITION FOR FILM FORMATION, PATTERN FORMATION METHOD, INSULATING FILM FORMATION METHOD, AND METHOD FOR PRODUCING COMPOUND, AS WELL AS METHOD FOR PRODUCING IODINE-CONTAINING VINYL POLYMER AND ACETYLATED DERIVATIVE THEREOF MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2022-11-03 US disclosed
CN-114245792-A Compound, polymer, composition for film formation, method for pattern formation, method for forming insulating film, method for producing compound, and method for producing iodine-containing vinyl polymer and acetylated derivative thereof 三菱瓦斯化学株式会社 2022-03-25 CN disclosed
US-20220073722-A1 COMPOSITION AND MOLDED ARTICLE AKITA UNIVERSITY (JP) 2022-03-10 US disclosed
US-20210060042-A1 Patentiflorin A Analogs as Antiviral Agents HONG KONG BAPTIST UNIVERSITY (HK) 2021-03-04 US disclosed
WO-2021029395-A1 COMPOUND, POLYMER, COMPOSITION, COMPOSITION FOR FILM FORMATION, PATTERN FORMING METHOD, METHOD FOR FORMING INSULATING FILM, METHOD FOR PRODUCING COMPOUND, IODINE-CONTAINING VINYL POLYMER AND METHOD FOR PRODUCING ACETYLATED DERIVATIVE OF SAME 三菱瓦斯化学株式会社 2021-02-18 WO disclosed
WO-2021029395-A1 COMPOUND, POLYMER, COMPOSITION, COMPOSITION FOR FILM FORMATION, PATTERN FORMING METHOD, METHOD FOR FORMING INSULATING FILM, METHOD FOR PRODUCING COMPOUND, IODINE-CONTAINING VINYL POLYMER AND METHOD FOR PRODUCING ACETYLATED DERIVATIVE OF SAME 三菱瓦斯化学株式会社 2021-02-18 WO disclosed
US-10815369-B2 Composition and molded article AKITA UNIVERSITY (JP) 2020-10-27 US disclosed
US-20190169415-A1 COMPOSITION AND MOLDED ARTICLE AKITA UNIVERSITY (JP) 2019-06-06 US disclosed
US-7973031-B2 Leukemia therapy ;myelodyspastic syndrome NOVARTIS AG (CH) 2011-07-05 US disclosed
US-20100184820-A1 COMBINATIONS COMPRISING STAUROSPORINES NOVARTIS AG (CH) 2010-07-22 US disclosed
US-20100184820-A1 COMBINATIONS COMPRISING STAUROSPORINES NOVARTIS AG (CH) 2010-07-22 US disclosed
US-20090286770-A1 Use of Staurosporine Derivatives for the Treatment of Multiple Myeloma NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR 2009-11-19 US disclosed
US-20090286770-A1 Use of Staurosporine Derivatives for the Treatment of Multiple Myeloma NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR 2009-11-19 US disclosed
US-20080159954-A1 METAL CHELATES HAVING A PERFLUORINATED PEG RADICAL, PROCESSES FOR THEIR PREPARATION, AND THEIR USE BAYER INTELLECTUAL PROPERTY GMBH (DE) 2008-07-03 US disclosed
US-20070299049-A1 Pharmaceutical Uses of Staurosporine Derivatives NOVARTIS PHARMACEUTICALS CORPORATION 2007-12-27 US disclosed
US-20070299049-A1 Pharmaceutical Uses of Staurosporine Derivatives NOVARTIS PHARMACEUTICALS CORPORATION 2007-12-27 US disclosed
US-7163997-B2 Polyether derivative and process for producing the same FUJI PHOTO FILM CO., LTD. (JP) 2007-01-16 US disclosed
US-7163997-B2 Polyether derivative and process for producing the same FUJI PHOTO FILM CO., LTD. (JP) 2007-01-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080159954-A1 METAL CHELATES HAVING A PERFLUORINATED PEG RADICAL, PROCESSES FOR THEIR PREPARATION, AND THEIR USE TFRC, FCGRT, SLC39A14 CA5A 3177/4885MAPT 470/4885RAB9A 1108/4885
US-20090286770-A1 Use of Staurosporine Derivatives for the Treatment of Multiple Myeloma FOS, MYC, MCL1 CA5A 2302/4885MAPT 3608/4885RAB9A 2800/4885
US-20070299049-A1 Pharmaceutical Uses of Staurosporine Derivatives BAK1, BAD, MAST1 CA5A 1029/4885MAPT 1468/4885RAB9A 3366/4885
US-20100184820-A1 COMBINATIONS COMPRISING STAUROSPORINES MCL1, FLT3, BCL3 CA5A 3918/4885MAPT 4300/4885RAB9A 4667/4885
US-20210060042-A1 Patentiflorin A Analogs as Antiviral Agents MAVS, MIF, SARS1 CA5A 2924/4885MAPT 2419/4885RAB9A 3511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.